Kanada - Inggeris - Health Canada

rockwell medical inc - iron (ferric pyrophosphate citrate) - solution - 1.5mg - iron (ferric pyrophosphate citrate) 1.5mg - iron preparations

Singapura - Inggeris - HSA (Health Sciences Authority)

goldplus universal pte ltd - iron (iii) hydroxide polymaltose complex eqv elemental iron - capsule - iron (iii) hydroxide polymaltose complex eqv elemental iron 100 mg

Singapura - Inggeris - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - (iron layer) dried ferrous sulphate eqv elemental iron; (lubricating) folic acid; (lubricating) vitamin b12 oral powder in lactose; (vitamin layer) niacinamide; (vitamin layer) pyridoxine hydrochloride; (vitamin layer) riboflavin; (vitamin layer) thiamine mononitrate; (vitamin layer) ascorbic acid; (vitamin layer) calcium pantothenate - tablet, film coated - 500 mg - (iron layer) dried ferrous sulphate eqv elemental iron 105 mg; (lubricating) folic acid 800 mcg; (lubricating) vitamin b12 oral powder in lactose 25.0 mcg; (vitamin layer) niacinamide 30 mg; (vitamin layer) pyridoxine hydrochloride 5 mg; (vitamin layer) riboflavin 6 mg; (vitamin layer) thiamine mononitrate 6 mg; (vitamin layer) ascorbic acid 500 mg; (vitamin layer) calcium pantothenate 10 mg

Malaysia - Inggeris - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

baxter healthcare (malaysia) sdn. bhd. - iron (iii)- hydroxide sucrose complex -

Malaysia - Inggeris - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

unimed sdn bhd - iron (iii)- hydroxide sucrose complex -

Kenya - Inggeris - Pharmacy and Poisons Board

iron sucrose complex equivalent to elemental iron - solution for injection - 20mg/ml - antianemic preparations - iron preparations: iron

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - iron polymaltose 50 mg/ml (159mg/ml iron hydroxide polymaltose complex =50mg/ml iron) - solution for injection - 100mg/2ml - active: iron polymaltose 50 mg/ml (159mg/ml iron hydroxide polymaltose complex =50mg/ml iron) excipient: hydrochloric acid sodium hydroxide water for injection - for the prevention and treatment of iron deficiency anaemia in the following circumstances: · when oral therapy is contraindicated · when enteric absorption of iron is defective · when patient non-compliance or persistent gastrointestinal intolerance makes oral therapy impractical · treating iron deficiency anaemia of prematurity and that occurring in geriatric patients · treating iron deficiency states discovered in the third trimester of pregnancy · anaemia resulting from excessive blood loss · where contact between the doctor and patient occurs at irregular intervals

Kenya - Inggeris - Pharmacy and Poisons Board

surge laboratories (pvt). ltd. 5th floor commerce centre hasrat mohani road, - iron sucrose complex - injection - iron sucrose complex eq. to elemental iron… - antithrombotic agents: platelet aggregation

Kenya - Inggeris - Pharmacy and Poisons Board

hilton pharma pvt. ltd c/o surgilinks ltd plot 13 /15 korangi industrial area karachi - iron iii hydroxide polymaltose complex eq. to… - tablet - iron 111 polymaltose complex eq. to elemental… - antianemic preparations - iron preparations: iron

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

a-s medication solutions - iron sucrose (unii: fz7nyf5n8l) (ferric cation - unii:91o4lml611) - venofer is indicated for the treatment of iron deficiency anemia (ida) in patients with chronic kidney disease (ckd). - known hypersensitivity to venofer. risk summary published studies on intravenous iron sucrose treatment after the first trimester of pregnancy have not shown adverse maternal or fetal outcomes (see data) . available reports of intravenous iron sucrose use in pregnant women during the first trimester are insufficient to assess the risk of major birth defects and miscarriage. there are risks to the mother and fetus associated with untreated ida in pregnancy as well as risks to the fetus associated with maternal severe hypersensitivity reactions (see clinical considerations) . animal reproduction studies of iron sucrose administered to rats and rabbits during the period of organogenesis at elemental iron doses equivalent to the maximum recommended human dose based on body surface area revealed no evidence of harm to the fetus (see data). the estimated background risk of major birth defects and